新型口服抗凝药物用于房颤患者抗凝治疗的研究进展  

Novel Oral Anticoagulants in Atrial Fibrillation

作　　者：张帆[1] 宋沧桑[1] 

机构地区：[1]云南昆明市第一人民医院药学部,昆明650011

出　　处：《海峡药学》2016年第2期94-96,共3页Strait Pharmaceutical Journal

摘　　要：房颤是临床常见且严重的心律失常之一,脑卒中是房颤最常见和危险的并发症,口服抗凝药物是防治并发症的关键手段。新型口服抗凝药的研发克服了华法林治疗窗窄、需要长期监测INR的弊端,但也有许多临床试验在证明新型口服抗凝药疗效的同时,验证和发现了出血、肝损伤等不良反应。现将新型口服抗凝药物用于房颤患者抗凝治疗的研究进展做一综述。Atrial fibrillation is the most commom and serious arrhythmia,stroke is its most commom and serious complication. Oral anticoagulants is the important means to prevent and treat the complication of AF. Novel oral anticoagulants can conquer the disadvantage of Warfarin. Many clinical tests have verified the efficacy in novel oral anticoagulants,but the ADRs of novel oral anticoagulants were found also,such as bleeding and liver injury. Here progress in novel oral anticoagulants was reviewed.

关 键 词：房颤 新型口服抗凝药 华法林 临床试验 

分 类 号：R969.4[医药卫生—药理学]